Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Multiple Myeloma × durvalumab × Clear all

Phase

Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 69 Lung Neoplasms 32 Carcinoma, Hepatocellular 31 Small Cell Lung Carcinoma 23 Cholangiocarcinoma 16 Urinary Bladder Neoplasms 15 Neoplasms 14 Breast Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 12 Colorectal Neoplasms 12 Triple Negative Breast Neoplasms 11 Esophageal Neoplasms 8 Stomach Neoplasms 7 Pancreatic Neoplasms 7 Ovarian Neoplasms 7 Liver Neoplasms 7 Biliary Tract Neoplasms 7 Recurrence 6 Prostatic Neoplasms 6 Neoplasm Metastasis 6 Melanoma 6 Head and Neck Neoplasms 6 Carcinoma, Transitional Cell 6 Neoplasms by Site 5 Carcinoma, Renal Cell 5 Bile Duct Neoplasms 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4 Respiratory Tract Neoplasms 4 Mesothelioma, Malignant 4

Interventions

Dexamethasone 294 Bortezomib 160 Lenalidomide 155 Cyclophosphamide 143 Melphalan 107 Calcium Dobesilate 93 daratumumab 82 pomalidomide 58 carfilzomib 58 fludarabine phosphate 53 Peripheral Blood Stem Cell Transplantation 53 Thalidomide 46 Filgrastim 46 Mycophenolic Acid 42 Busulfan 42 ixazomib 39 fludarabine 36 Granulocyte Colony-Stimulating Factor 35 Whole-Body Irradiation 34 Tacrolimus 34 dexamethasone acetate 29 Etoposide 28 Cyclosporine 28 Antilymphocyte Serum 27 isatuximab 25 dexamethasone 21-phosphate 24 auricularum 23 plerixafor 21 Radiotherapy 21 elotuzumab 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03000452 2018-10-16

FUSION-MM-005

Celgene

Phase 2 Completed

18 enrolled 16 charts

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡